RxDoctor Payments Data

Rachael Faught, DO

Internal Medicine · Jackson, MSNPI 1043522352

Payments from drug & device makers

$4,322in general payments, 2019–2025

Across 224 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$698
  • Mallinckrodt Hospital Products Inc.$512
  • Sanofi$244
  • Pfizer$205
  • Verona Pharma, Inc.$157
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,322 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$114,728
Medicare patients
330
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter269$190,048
Breztri AerosphereBudesonide/Glycopyr/Formoterol240$154,835
Breo ElliptaFluticasone/Vilanterol64$25,778
Albuterol Sulfate HfaAlbuterol Sulfate397$11,269
Combivent RespimatIpratropium/Albuterol Sulfate16$10,041
XareltoRivaroxaban11$6,162
BreynaBudesonide/Formoterol Fumarate30$5,280
SymbicortBudesonide/Formoterol Fumarate15$3,726
Ventolin HfaAlbuterol Sulfate67$3,692
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,297
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,353
Bupropion Hcl SrBupropion Hcl15$441
Azithromycin34$375
Fluticasone Propionate41$357
Prednisone104$276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$698$215,826333 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,327$158,561255 claims
Boehringer IngelheimCombivent Respimat$132$10,04116 claims
Johnson & JohnsonXarelto$138$6,16211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →